- $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger Technology to Optimize CAR T Cell Expansion and Persistence
Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.